The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ERIC 2024 | The advancements and remaining challenges in precision medicine for CLL
Richard Rosenquist, MD, PhD, Karolinska Institute, Solna, Sweden, speaks about the advancements and remaining challenges in precision medicine for chronic lymphocytic leukemia (CLL). He highlights the transition from chemoimmunotherapy to targeted therapies such as BTK and BCL2 inhibitors, while addressing ongoing challenges in treatment sequencing and patient response. Prof. Rosenquist emphasizes the need for deep molecular profiling alongside new therapies to develop predictive markers for treatment response. This interview took place at the 2024 European Research Initiative on CLL (ERIC) Meeting in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Honoraria: AbbVie, AstraZeneca, Illumina, Janssen and Roche.
